CSTL:NASDAQ, Castle Biosciences, Inc.
CSTL stock overview
Castle Biosciences, Inc. (CSTL:NASDAQ) closed at $33.08 on October 23, 2026,
down 0.33% on the day.
The stock trades 25.3% below its 52-week high of $44.28
and 86.7% above its 52-week low of $17.72.
Over the past year, it gained 35.0%.
Castle Biosciences, Inc. is part of the Health Care sector (Medical Specialities).
Key figures
- Price
- $33.08
- Day change
- -0.33%
- Volume
- 203,016
- Average volume
- 402,989
- Market cap
- 1B+
- 52-week range
- $17.72 – $44.28
- 50-day average
- $33.64
- 200-day average
- $28.66
Price action over the past year
In 252 trading sessions since October 23, 2025, CSTL closed higher on 133 days (53%).
Its best day was November 4, 2025 (+21.70%) and its worst was May 7, 2026 (-22.26%).
The stock moved 10% or more in a single session 4 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
CSTL news
-
Oct 15, 2026:
Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026
-
Oct 12, 2026:
ACG 2026 Data Show TissueCypher Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus
-
Oct 12, 2026:
ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus
-
Oct 9, 2026:
New Melanoma Study Backing DecisionDx-Melanoma Could Be A Game Changer For Castle Biosciences (CSTL)
-
Sep 30, 2026:
Late-Breaking EADV 2026 Data Support Use of DecisionDx-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
-
Sep 30, 2026:
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
-
Sep 28, 2026:
New Study Shows That TissueCypher Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
-
Sep 28, 2026:
New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
About Castle Biosciences, Inc.
Castle Biosciences Inc is a United States-based company engaged in developing and commercializing diagnosis and prognostic tests for dermatologic cancers. Its non-invasive products utilize algorithms to provide an assessment of a patient's specific risk of metastasis or recurrence of their cancer. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
Similar stocks
Find more stocks like CSTL with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.